Jonathan James

Neoadjuvant chemotherapy is increasingly used as the primary treatment for women with breast cancer. Imaging is crucial for patient management by determining disease extent at diagnosis, monitoring response to treatment and for post-treatment surgical planning.  Traditionally, the imaging tool of choice is MRI because of its superior diagnostic accuracy compared to mammography, ultrasound and clinical examination.  Contrast enhanced mammography (CEM) has demonstrated similar performance to breast MRI in the diagnosis and staging of breast cancer, but does it have a role in assessing women undergoing neoadjuvant chemotherapy?

This talk will look at the available evidence for using CEM to predict treatment response and using clinical examples, will consider the advantages and disadvantages of CEM and MRI in this setting.